487 related articles for article (PubMed ID: 19058920)
1. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
2. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
3. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
6. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
8. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
9. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
[TBL] [Abstract][Full Text] [Related]
10. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women.
Ivaldi GB; Leonardi MC; Orecchia R; Zerini D; Morra A; Galimberti V; Gatti G; Luini A; Veronesi P; Ciocca M; Sangalli C; Fodor C; Veronesi U
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):485-93. PubMed ID: 18407434
[TBL] [Abstract][Full Text] [Related]
13. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Breteau N; Body G; Azria D; Le Floch O; Calais G
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):324-32. PubMed ID: 16542788
[TBL] [Abstract][Full Text] [Related]
14. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
[TBL] [Abstract][Full Text] [Related]
16. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy.
Vicini FA; Chen P; Wallace M; Mitchell C; Hasan Y; Grills I; Kestin L; Schell S; Goldstein NS; Kunzman J; Gilbert S; Martinez A
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1124-30. PubMed ID: 17967306
[TBL] [Abstract][Full Text] [Related]
17. Radioprotective effect of moderate wine consumption in patients with breast carcinoma.
Morganti AG; Digesù C; Panunzi S; De Gaetano A; Macchia G; Deodato F; Cece MG; Cirocco M; Di Castelnuovo A; Iacoviello L; Valentini V; Cellini N; de Gaetano G
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1501-5. PubMed ID: 19395196
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy for breast cancer patients treated by breast-conserving surgery: short-term morbidity and preliminary results.
Plataniotis GA; Theofanopoulou MA; Sotiriadou K; Kyrgias G
Breast Cancer; 2010; 17(1):42-7. PubMed ID: 19350358
[TBL] [Abstract][Full Text] [Related]
19. Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery.
Kraus-Tiefenbacher U; Bauer L; Scheda A; Fleckenstein K; Keller A; Herskind C; Steil V; Melchert F; Wenz F
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):377-81. PubMed ID: 16887294
[TBL] [Abstract][Full Text] [Related]
20. TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer.
Perera F; Chisela F; Stitt L; Engel J; Venkatesan V
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1283-90. PubMed ID: 16029783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
